Improvements in Pain and Disability Contribute to Improved Quality of Life After Inebilizumab Treatment in Attack-Free Neuromyelitis Optica Spectrum Disorder (NMOSD) Participants (P11-8.008)
Here we further evaluated Pain and QoL improvement in attack-free, inebilizumab-treated participants over 3-years to determine improvements in non-attack related Pain and QoL.
Authors
- Bruce Cree (ORCID: https://orcid.org/0000-0001-7689-2533)
- William A. Rees (ORCID: https://orcid.org/0000-0003-1857-8364)
- Orhan Aktaş (ORCID: https://orcid.org/0000-0002-2020-9210)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Jodie Burton (ORCID: https://orcid.org/0000-0003-0475-9535)
- Kristina R. Patterson (ORCID: https://orcid.org/0000-0002-6421-6869)
- Douglas Kazutoshi Sato (ORCID: https://orcid.org/0000-0002-7695-6020)
- Michael A. Smith (ORCID: https://orcid.org/0009-0005-3694-3187)
Institutions
- Amgen (United States) (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Heinrich Heine University Düsseldorf (DE)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Charité - Universitätsmedizin Berlin (DE)
- University of Rio Grande and Rio Grande Community College (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209098
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00